MCID: LKM056
MIFTS: 35

Leukemia, Chronic Lymphocytic 2

Categories: Immune diseases, Cancer diseases, Blood diseases, Rare diseases

Aliases & Classifications for Leukemia, Chronic Lymphocytic 2

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic 2:

Name: Leukemia, Chronic Lymphocytic 2 53 28
Leukemia, Chronic Lymphocytic, Susceptibility to, 2 53 13
B-Cell Malignancy, Low-Grade 53 69
Leukemia, Chronic Lymphocytic, B-Cell; Bcll 53
Leukemia, Chronic Lymphocytic, B-Cell 53
Disrupted in B-Cell Malignancy; Dbm 53
Disrupted in B-Cell Malignancy 53
Chronic Lymphocytic Leukemia 69
Clls2 53
Bcll 53
Dbm 53

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant (13q14)


HPO:

31
leukemia, chronic lymphocytic 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 109543
MedGen 39 C1868683
UMLS 69 C1868683

Summaries for Leukemia, Chronic Lymphocytic 2

MalaCards based summary : Leukemia, Chronic Lymphocytic 2, also known as leukemia, chronic lymphocytic, susceptibility to, 2, is related to leukemia, chronic lymphocytic and prostate cancer, and has symptoms including chronic lymphatic leukemia, fatigue and edema. An important gene associated with Leukemia, Chronic Lymphocytic 2 is CLLS2 (Disrupted In B-Cell Neoplasia). The drugs Chlorambucil and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells.

Description from OMIM: 109543

Related Diseases for Leukemia, Chronic Lymphocytic 2

Diseases in the Acute Lymphocytic Leukemia family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic
Leukemia, Chronic Lymphocytic 1 Leukemia, Chronic Lymphocytic 3
Leukemia, Chronic Lymphocytic 4 Leukemia, Chronic Lymphocytic 5
Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 10.9
2 prostate cancer 9.8
3 leukemia 9.8

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic 2

Symptoms via clinical synopsis from OMIM:

53
Oncology:
b-cell chronic lymphocytic leukemia (cll)


Clinical features from OMIM:

109543

Human phenotypes related to Leukemia, Chronic Lymphocytic 2:

31
# Description HPO Frequency HPO Source Accession
1 chronic lymphatic leukemia 31 HP:0005550

UMLS symptoms related to Leukemia, Chronic Lymphocytic 2:


fatigue, edema, chest pain, angina pectoris

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic 2

Drugs for Leukemia, Chronic Lymphocytic 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
4
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
5
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24356-66-9 21704 32326
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
13 Antibodies Phase 4,Phase 2,Phase 1
14 Antibodies, Monoclonal Phase 4,Phase 1,Phase 2
15 Immunoglobulins Phase 4,Phase 2,Phase 1
16
alemtuzumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216503-57-0
17
Adenosine Approved, Investigational Phase 3,Phase 2,Phase 1 58-61-7 60961
18
Pentostatin Approved, Investigational Phase 3,Phase 2,Phase 1 53910-25-1 439693 40926
19
Cladribine Approved, Investigational Phase 3,Phase 1,Phase 2 4291-63-8 20279
20
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
21
Cisplatin Approved Phase 3,Phase 1 15663-27-1 2767 441203 84093
22
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2 147-94-4 6253
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
24
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
25
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
27
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
28
Lenalidomide Approved Phase 3,Phase 2,Phase 1,Not Applicable 191732-72-6 216326
29
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
30 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 BB 1101 Phase 3,Phase 2,Phase 1
35 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
36 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 glucocorticoids Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
39 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
43
protease inhibitors Phase 3,Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
45 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
46 Methylprednisolone acetate Phase 3,Phase 2,Not Applicable
47 Methylprednisolone Hemisuccinate Phase 3,Phase 2,Not Applicable
48 Prednisolone acetate Phase 3,Phase 2,Not Applicable
49 Prednisolone hemisuccinate Phase 3,Phase 2,Not Applicable
50 Prednisolone phosphate Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 217)

# Name Status NCT ID Phase Drugs
1 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
2 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4 Ofatumumab
3 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
4 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
5 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3
6 Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
7 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
8 FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
9 A Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chronic Lymphocytic Leukemia Completed NCT00718549 Phase 3 cladribine;cyclophosphamide;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
10 Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP Completed NCT00564512 Phase 3 cyclophosphamide;fludarabine
11 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
12 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
13 Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
14 Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate
15 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
16 Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia Completed NCT00645606 Phase 3
17 Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia Completed NCT00004218 Phase 3 chlorambucil;cyclophosphamide;doxorubicin hydrochloride;fludarabine phosphate;prednisolone;vincristine sulfate
18 Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia Completed NCT00003764 Phase 3 cyclophosphamide;fludarabine phosphate
19 A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy Active, not recruiting NCT00774345 Phase 3 Lenalidomide;Placebo
20 Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) Active, not recruiting NCT00910910 Phase 3 Lenalidomide;Chlorambucil
21 Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Terminated NCT00513747 Phase 3 fludarabine phosphate
22 Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) Unknown status NCT01295593 Phase 1, Phase 2 valproic acid and 2-chlorodeoxyadenosine
23 Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy Unknown status NCT00800943 Phase 2
24 Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia Unknown status NCT00074282 Phase 2 cyclophosphamide;lenalidomide;pentostatin
25 Rituximab in Pretreated Elderly or Unfit B-CLL Patients Unknown status NCT01576588 Phase 2 Rituximab;Glucocorticoid
26 Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) Unknown status NCT00927797 Phase 2 Cyclophosphamide, Pentostatin, Rituximab
27 Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Unknown status NCT00628238 Phase 2 Lenalidomide and Rituximab;Lenalidomide and Rituximab
28 Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine Unknown status NCT01392079 Phase 2 Alemtuzumab
29 Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia Unknown status NCT00983528 Phase 1, Phase 2 Clofarabine
30 Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia Unknown status NCT01269385 Phase 1, Phase 2 PGG beta-glucan
31 Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Unknown status NCT01024010 Phase 2 pentostatin;cyclophosphamide
32 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
33 Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00026429 Phase 2
34 Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome Unknown status NCT01171378 Phase 2 Ofatumumab
35 Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Completed NCT01144260 Phase 2 bafetinib
36 AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia Completed NCT00321724 Phase 2 cediranib maleate
37 Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia Completed NCT00082940 Phase 2
38 Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia Completed NCT00086775 Phase 2 fludarabine phosphate
39 Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Completed NCT00328198 Phase 2
40 Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia Completed NCT00274989 Phase 2 Bendamustine
41 Intensified Rituimab Prephase Before FCR in Untreated B-CLL Completed NCT01370772 Phase 2 Rituximab;Rituximab;Cyclophosphamide;Fludarabine
42 Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia Completed NCT00003248 Phase 2 fludarabine phosphate
43 Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00162851 Phase 2 alemtuzumab
44 Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) Completed NCT00147901 Phase 2 FCCam
45 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) Completed NCT00206726 Phase 2 Alemtuzumab plus Fludarabine
46 Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00634881 Phase 1, Phase 2
47 A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia Completed NCT01558167 Phase 1, Phase 2 Bendamustine, Rituximab, Lenalidomide
48 Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM Completed NCT00648739 Phase 1, Phase 2 ALXN6000
49 HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab Completed NCT00349349 Phase 2 ofatumumab
50 Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT00274963 Phase 2 bendamustine hydrochloride;mitoxantrone hydrochloride

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic 2

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Leukemia, Chronic Lymphocytic 2

Genetic tests related to Leukemia, Chronic Lymphocytic 2:

# Genetic test Affiliating Genes
1 Leukemia, Chronic Lymphocytic 2 28

Anatomical Context for Leukemia, Chronic Lymphocytic 2

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic 2:

38
B Cells

Publications for Leukemia, Chronic Lymphocytic 2

Articles related to Leukemia, Chronic Lymphocytic 2:

(show top 50) (show all 2875)
# Title Authors Year
1
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
2
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. ( 29450641 )
2018
3
Gamma heavy chain disease evolving during the progression of chronic lymphocytic leukemia. ( 29315075 )
2018
4
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
5
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
6
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. ( 29449433 )
2018
7
Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )
2018
8
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? ( 29402474 )
2018
9
Disseminated cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia. ( 29428267 )
2018
10
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28073846 )
2017
11
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
12
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. ( 28639485 )
2017
13
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. ( 28931525 )
2017
14
Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. ( 28893099 )
2017
15
S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-I_B activity during disease progression. ( 28596424 )
2017
16
Chronic Lymphocytic Leukemia: Individualizing Treatment Approach. ( 28515252 )
2017
17
Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. ( 27757836 )
2017
18
Venetoclax for the treatment of patients with chronic lymphocytic leukemia. ( 28492339 )
2017
19
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. ( 28517553 )
2017
20
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. ( 28924241 )
2017
21
Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. ( 28192408 )
2017
22
Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies. ( 29381944 )
2017
23
Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting. ( 28824637 )
2017
24
Wnt5a induces ROR1 to associate with 14-3-3IP for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. ( 28465528 )
2017
25
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. ( 28499646 )
2017
26
Infectious complications in chronic lymphocytic leukemia- a retrospective analysis: single institution experience. ( 28503927 )
2017
27
NF-I_B p50 (nfkb1) contributes to pathogenesis in the EI1-TCL1 mouse model of chronic lymphocytic leukemia. ( 28515090 )
2017
28
Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation. ( 28476805 )
2017
29
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. ( 28091403 )
2017
30
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ ATM FISH deletions. ( 28493833 )
2017
31
Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia. ( 28833505 )
2017
32
Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients. ( 28699185 )
2017
33
HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia. ( 27859015 )
2017
34
Intravascular large B-cell lymphoma presenting as Richter's syndrome with cerebral involvement in a patient with chronic lymphocytic leukemia. ( 28878900 )
2017
35
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. ( 28321119 )
2017
36
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. ( 28495642 )
2017
37
The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling. ( 28982149 )
2017
38
Two Distinct BCL2 Rearrangements, Each Observed in 2 Independent Subclones, Evolving from a Founder Clone with Trisomy 12 in a Unique Case of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28514780 )
2017
39
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. ( 28062113 )
2017
40
Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. ( 28465529 )
2017
41
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. ( 28077600 )
2017
42
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
43
Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia. ( 28160756 )
2017
44
State of the Art in MicroRNA as Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia. ( 28084621 )
2017
45
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. ( 29296799 )
2017
46
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. ( 28526063 )
2017
47
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. ( 28935694 )
2017
48
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. ( 28718694 )
2017
49
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. ( 28903342 )
2017
50
The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia. ( 28083607 )
2017

Variations for Leukemia, Chronic Lymphocytic 2

Expression for Leukemia, Chronic Lymphocytic 2

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic 2.

Pathways for Leukemia, Chronic Lymphocytic 2

GO Terms for Leukemia, Chronic Lymphocytic 2

Sources for Leukemia, Chronic Lymphocytic 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....